
BioSpace
BioSpaceAudio
- Format:
- Podcast
- New episodes:
- Several times a week
- Typical length:
- about 20 minutes
- Latest episode:
About this show
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Show details and episodes come from the publisher's public feed at api.riverside.fm. Last updated . Names, artwork and text belong to their publishers.
Cosmos
Similar by topic and creator
- Rain and Thunder Storms Podcast
Shares the topic Science. - Simons Foundation Lectures
Shares the topic Science. - Deep Sleep Thunderstorm Sounds
Shares the topic Science.
Similar shows
Explore more
Episodes
Can we finally get ahead of drug shortages?
· 20 min
In this episode of Denatured, you'll hear from Christina Smolke, co-founder & CEO at Antheia and Kyle Pudenz, senior vice president and head of data & AI product at Cencora. We explore why drug shortages are getting worse, and how combining predictive supply-chain analytics with agile, distributed manufacturing could finally make essential medicines more resilient and accessible. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Christina Smolke (https://www.linkedin.com/in/christina-smolke-87a8b3b6/), Co-founder & CEO, Antheia Kyle Pudenz (https://www.linkedin.com/in/dr-kyle-pudenz/), Senior Vice President, Head of Data & AI Product, Cencora Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetNovartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
· 23 min
Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a rare eye condition that can lead to vision loss; and the agency is set to decide on no fewer than 11 therapies this month, including closely watched applications from Summit Therapeutics, Vertex and Capricor Therapeutics.
Not rated yetBeyond the needle: The future of intratumoral therapy
· 21 min
In this episode of Denatured, you’ll hear from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies trigger systemic anti-cancer immunity from a local injection, and redefine a foundational platform in immuno-oncology. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Lewis Bender (https://www.linkedin.com/in/lewis-bender-7b5a7a7/), President & CEO, Intensity Therapeutics Paul-Peter Tak (https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/), President, CEO and Board Director, Candel Therapeutics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetQ3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
· 23 min
The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerating rare disease treatments; HHS greenlights the compounding of six unapproved peptides; and uniQure’s embattled gene therapy for Huntington’s disease has finally been accepted for review.
Not rated yetStability, speed and strategy: Inside Australia’s early‑stage edge
· 21 min
In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Jerome Barley (https://www.linkedin.com/in/jerome-barley/), Commercial Director, Avion Medical Ryan Klein (https://www.linkedin.com/in/ryanrklein/), Vice President, Business Development, US and APAC, Resolian Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetData leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
· 23 min
Merck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine leaking prior to the presentation and antibody-drug conjugate sac-TMT making a splash in endometrial cancer; Bristol Myers Squibb revealed the death of a patient with multiple sclerosis in an early-stage trial of zola-cel; and pharma is on track to easily surpass last year’s deal count.
Not rated yetWhy investors are taking another look at kidney disease
· 18 min
In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Bruce Culleton (https://www.linkedin.com/in/bruce-culleton-424b827/), CEO, ProKidney Demetri Maxim (https://www.linkedin.com/in/demetri-maxim/), CEO, Nephrogen Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetDisc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
· 17 min
China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck and Summit Therapeutics.
Not rated yetBonus: Q3 2026 Job Market Update
· 16 min
BioSpace Vice President Chantal Dresner and Angela Gabriel, content manager, life sciences careers, cover what happened in the biopharma job market during the third quarter. They discuss encouraging signs for those looking for their next opportunity, such as improved job postings live on the BioSpace website and a dramatic drop in layoffs. Other topics include signs of industry health, news about job opportunities and advice for the Q4 job hunt.
Not rated yetThe decisions behind scientific progress
· 10 min
In this episode of Denatured, sponsored by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we discuss how biopharma has long invested in more data and visibility, yet many programs still face delays and scale-up surprises. The real challenge isn’t information overload—it’s building confidence in the decisions that steer scientific progress from development through commercialization. This episode is presented in partnership with Cytiva (https://www.cytivalifesciences.com/en/us). Host Jennifer Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guest Nicolas Pivet, (https://www.linkedin.com/in/nicolas-pivet-a30b891b/) VP & GM, Manufacturing & Digital Solutions, Cytiva Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations
Not rated yetJ&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
· 19 min
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out.
Not rated yetBeyond equity: Why venture debt is reshaping European biotech
· 22 min
In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t — and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Jennifer McMahon (https://www.linkedin.com/in/jennifer-mcmahon-564b6835/), Partner, Seroba Joey Mason (https://www.linkedin.com/in/joey-mason/), Venture Partner, Claret Capital Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetGenmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
· 24 min
New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?
Not rated yetThe race for access: How the FAIR Act could reclaim U.S. biotech leadership
· 20 min
In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Max Bronstein (https://www.linkedin.com/in/maxgbronstein/), CEO, Aviva Strategies Teresa Barnes (https://www.linkedin.com/in/teresa-barnes-85a30814/), Chief Executive Warrior, PF Warriors Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetAstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
· 20 min
Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.
Not rated yetHow radioligand therapy is rewriting cancer care
· 15 min
In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of Global Clinical Development. We examine radioligand therapy’s accelerating momentum and how its diagnostic and therapeutic reach could potentially reshape care for more than 14 million patients worldwide. We also discuss Curium's push to expand US capacity and scale up at pace, and critically what success could mean for patients with cancer in the years ahead. This episode is presented in partnership with Curium (https://www.curiumpharma.com/). Host Jennifer Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Mike Patterson (https://www.linkedin.com/in/michael-patterson-7653011a/), CEO North America, Curium Sabine Brookman-May (https://www.linkedin.com/in/prof-dr-med-sabine-d-brookman-may-48115728/), VP and Head of Global Clinical Development, Curium Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetNovo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
· 21 min
Novo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to turn things around; Viking Therapeutics and Roche report positive results for their weight loss assets; Ultragenyx snags FDA approval for its Sanfilippo syndrome gene therapy; IPOs keep on coming.
Not rated yetWhen vision fades: Rethinking wet AMD and the durability gap
· 21 min
In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and Wesley Jackson, chief science officer at Valitor. We talk about the eye condition call wet age-related macular degeneration (AMD), the limits of anti‑VEGF therapy and the push for true durability to change a patient’s life. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Philip Jacob Rosenfeld (https://theophthalmologist.com/power-list/2016/honorees/philip-j-rosenfeld/), Professor of Ophthalmology, University of Miami Health System, Bascom Palmer Eye Institute Wesley Jackson (https://www.linkedin.com/in/wesleymjackson/), Chief Science Officer, Valitor Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetFDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
· 22 min
The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fee Act the day after launching its TrialBlazer initiative. Meanwhile, Definium Therapeutics notched another late-stage trial win for its LSD drug, and Novartis continues to reel from the company’s triple asset stumble.
Not rated yetThe supply chain fault lines of modern pharma
· 36 min
In this episode of Denatured, sponsored by SK Pharmteco, Jennifer Smith-Parker speaks to Arvind Singh, vice president and global head of supply chain. In this episode, we discuss how CDMOs are revamping supply‑chain strategy for a new generation of intricate modalities. Topics addressed include moving from smarter raw‑material sourcing and precision cold‑chain logistics to navigating geopolitical and regulatory uncertainty and deploying AI to building sustainable, scalable capabilities from clinical through commercial. This episode is presented in partnership with SK Pharmteco (https://www.skpharmteco.com/). Host Jennifer Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guest Arvind Singh (https://www.linkedin.com/in/arvindsingh02/), VP & Global Head of Supply Chain Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yet